ProfileGDS5678 / 1438277_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 25% 24% 24% 24% 23% 35% 24% 25% 24% 24% 24% 24% 24% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5673223
GSM967853U87-EV human glioblastoma xenograft - Control 22.5690725
GSM967854U87-EV human glioblastoma xenograft - Control 32.5524824
GSM967855U87-EV human glioblastoma xenograft - Control 42.5155124
GSM967856U87-EV human glioblastoma xenograft - Control 52.5092324
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5999323
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8440835
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.542724
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5466725
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5511824
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5474924
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5371224
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5594924
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.560124